REGN910-3
R910-3-OD-1403
Phase 2 small_molecule completed
Quick answer
REGN910-3 for Neovascular Age-Related Macular Degeneration is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Neovascular Age-Related Macular Degeneration
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed